Global NewsNews

Binnopharm Group to acquire two anti-bacterial brands from Dr Reddy’s in Russia, CIS region

The two anti-bacterial brands Ciprolet and Levolet in Russia, Belarus and Uzbekistan strengthen its antibiotic portfolio

The Sistema Group company, Binnopharm Group, a leading pharmaceutical production company in Russia via its affiliate Joint Stock Company ‘Alium’, and Dr Reddy’s Laboratories announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solutions for infusions and eye drops.

Rustem Muratov, CEO, Binnopharm Group said, “The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers – according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets.”

MV Ramana, CEO – Branded Markets (India & Emerging Markets), said: “Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas to consolidate and strengthen our play further in our key focus therapy areas of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t Wait’.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close